RKLB -4.49ASTS -2.11MU 183.5501RHP 0.59MTRN 11.83PSMT 0ESLOY 0MSFT -14.25
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,122.39
+5.13 (0.46%)
as of Jun 25, 2026, 5:44:42 pm Market Open.
218 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 25, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Eli Lilly & Co. (LLY) is regarded as a leader in the diabetes and weight-loss drug market, particularly with its GLP-1 medications, which are poised for further growth as the company has ramped up production capabilities. Analysts expect strong earnings growth over the next few years, with favorable projections of up to 50% by 2026. While there is some volatility in the stock's performance due to competition and pricing differences, particularly from Novo Nordisk (NVO), Eli Lilly's diversified drug pipeline and financial strength provide a strong foundation. However, many experts suggest waiting for a pullback before entering, as the stock is experiencing high RSI levels and could be overbought. The anticipated introduction of an oral version of its weight-loss drug represents a potential game-changer that could expand market opportunities significantly, reinforcing the bullish outlook for LLY in the long run.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Fair Value
review icon
Similar
Amgen,AMGN
Unspecified

Eli Lilly & Co.(LLY)

Feb 27, 2023

It has outperformed the sector. The technicals are OK but but it is not in a great space. He owns some but would not buy more at this time.

Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
N/A

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
BUY

Eli Lilly & Co.(LLY)

Jan 27, 2023
It reports Thursday. He thinks their new drug will be the biggest seller of all time. He owns a lot of shares.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$342.10

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jan 25, 2023
Just announced a $450 million commitment to develop a promising diabetes drug that helps weight loss. The stock still has legs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$348.60

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Eli Lilly & Co.(LLY)

Jan 06, 2023
(A Top Pick Mar 14/22, Up 34%) Great company with high demand product (insulin). Building R&D portfolio that is on cutting edge. New drugs in the pipeline that will be approved. Weight loss products look promising.
Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$362.94

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
PARTIAL BUY

Eli Lilly & Co.(LLY)

Dec 09, 2022
Owns a big positions. Is a conservative company that doesn't hype itself or drugs which turns off some investors. Amazing diabetes, obesity and potentially Alzheimer drugs. Are having an analyst meeting on Tuesday, so wait after that to buy.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$363.79

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Dec 07, 2022
Super-excited about long-term prospects from new products, which could lead to 40% sales growth by 2025-26. These products will also increase margins. Biggest opportunity is within weight loss, initial results of a 3-year study are looking good, targeting obesity as well as its complications. Not cheap, but will continue to outperform. Yield is 1.05%. (Analysts’ price target is $381.39)
Photo of Michael Hakes - CFA, MBAMichael Hakes - CFA, MBA
Owned
Unlock Rating
$373.50

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Eli Lilly & Co.(LLY)

Oct 04, 2022
Allan Tong’s Discover Picks You could then take that money and put it in Eli Lilly. There’s potential in LLY stock’s own Alzheimer’s drug. Also, the street is putting its hopes into LLY’s weight-loss drug, Mounjaro, when it starts selling in two or three years. After all, diabetes as at an all-time high in America. One analyst envisioned $25 billion in peak sales, outstripping AbbVie‘s Humira which has topped $20.7 billion. However, the street is getting a little ahead of itself, since the FDA has approved Mounjaro for glycemic control in T2D patients, and LLY still needs to submit the drug as a treatment for weight-loss. Read Mixed bag of 3 Defensive Stocks for our full analysis.
Photo of Stockchase DiscoverStockchase DiscoverUnlock Rating
$329.89

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Eli Lilly & Co.(LLY)

Sep 21, 2022
A big holding. He almost bought more now. The drug stocks can go lower, but the future for Eli's weight-loss drug is huge and could be good for their Alzheimer's drug. Buy more when it breaks $280s.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$296.48

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Aug 24, 2022
Plenty of upside from its improved diabetes and obesity drug. Their Alzheimer's drug has potential As a drugmaker, it won't be hostage to a recession. Drugs will keep selling.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$318.87

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Aug 19, 2022
Around 15% topline growth. Likes healthcare, great fundamentals and 23% expected EPS growth.
Photo of Rob Sechan, Managing Partner, New Edge CapitalRob Sechan, Managing Partner, New Edge CapitalUnlock Rating
$324.57

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Aug 10, 2022
Focusing on its diabetes and weight loss drug. The weight loss drug could be one of the biggest drugs of all time, when it starts selling in the next 2-3 years.
Photo of Jamie Murray Jamie Murray
Owned
Unlock Rating
$302.93

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Jul 11, 2022
It seems cheap, because they have 4-7 billion-dollar drugs in their pipeline. So, estimates will have to move up dramatically and the PE will be lower. Therefore, the stock doesn't look as expensive as it seems.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$331.07

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

May 12, 2022
LLY vs. NVO NVO is focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd be OK on both.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$287.59

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Apr 25, 2022
Diabetes is an epidemic and LLY is a leader in therapeutics for this disease. Also it is making a major impact in the diagnostics and monitoring of Alzheimer's. Healthcare in general is one of the three best performing industries of all time but has under-performed until the beginning of this year. It has spun off its animal health division. It is defensive and timely in a bear market. Buy 16, Hold 8, Sell 1.
Photo of David FingoldDavid Fingold
Owned
Unlock Rating
$285.20

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Mar 28, 2022
Now, you need boring, low PE stocks, the opposite of those hurt by inflation, such as Alphabet or Meta. They sell at historically cheap PEs. In healthcare, Eli Lilly is his top pick.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$291.66

Stock price when the opinion was issued

$1122.39

As of Jun 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 136 to 150 of 205 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -14.25$351.21
PPL.TO 0.7$66.85
CVE.TO -0.09$35
TOU.TO 0.28$60.14
GOOG -5.48$339.56

Today's Top Picks

RKLB -4.49$80.92
ASTS -2.11$65.9
MU 183.55$1232.0601
RHP 0.59$130.36
MTRN 11.83$281.45

Popular Articles

Latest Sell Signals

ATD.TO -0.09$93.67
ITB 0.83$104.15
GLD 3.78$369.7
MU 183.55$1232.0601
MU 183.55$1232.0601

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica